Increased sensitivity of SPR assays in plasma through efficient parallel assay optimization

Journal of Pharmaceutical and Biomedical Analysis

Volumn 78-79, Issue , 2013, Pages 224-232

  Moberg, Anna ^a   Lager, Anna ^a   Hämäläinen, Markku D ^a   Jarhede, Tanja ^a  

^a BIACORE AB   (Sweden)

Author keywords

Anti drug antibodies (ADAs); Immunogenicity; Multivariate design of experiments (DoE); Non specific binding from plasma; Surface plasmon resonance (SPR) assay; Therapeutic antibody

Indexed keywords

ERYTHROPOIETIN ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; MYOGLOBIN; OMALIZUMAB; RITUXIMAB; SODIUM CHLORIDE;

ARTICLE; BIOSENSOR; CONCENTRATION (PARAMETERS); DRUG BINDING; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; LIMIT OF DETECTION; MOLECULAR MIMICRY; PARALLEL DESIGN; PH; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SENSITIVITY ANALYSIS; SURFACE PLASMON RESONANCE;

BIOSENSING TECHNIQUES; BLOOD CHEMICAL ANALYSIS; LIMIT OF DETECTION; MULTIVARIATE ANALYSIS; SURFACE PLASMON RESONANCE;

EID: 84875239931     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.02.018     Document Type: Article

References (16)

1. Guidance for Industry: Assay development for immunogenicity testing of therapeutic proteins. U.S. Food and Drug Administration [FDA] draft 2009 available from website , 2012 (accessed 8.11.12). http://www.fda.gov/downloads/Drugs/.../Guidances/UCM192750.pdf.
2. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1-16.
3. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267-1281.
4. Wang H., Cao C., Li B., Chen S., Yin J., Shi J., Ye D., Tao Q., Hu P., Epstein A., Ju D. Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients. Cancer Immunol. Immunother. 2008, 57:677-684.
5. Mytych D.T., La S., Barger T., Ferbas J., Swanson S.J. The development and validation of a sensitive, dual-flow cell. SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum. J. Pharm. Biomed. Anal. 2009, 49:415-426.
6. Jawa V., Hokom M., Hu Z., El-Abaadi N., Zhuang Y., Berger D., Gupta S., Swanson S.J., Chirmule N. Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Ann. Hematol. 2010, 89:75-85.
7. Hale G., Rebello P., Al Bakir I., Bolam E., Wiczling P., Jusko W.J., Vandemeulebroucke E., Keymeulen B., Mathieu C., Ziegler A.G., Chatenoud L., Waldmann H.J. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. Clin. Pharmacol. 2010, 50:1238-1248.
8. Lofgren J.A., Dhandapani S., Pennucci J.J., Abbott C.M., Mytych D.T., Kaliyaperumal A., Swanson S.J., Mullenix M.C., Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J. Immunol. 2007, 178:7467-7472.
9. van Schouwenburg P.A., Krieckaert C.L., Nurmohamed M., Hart M., Rispens T., Aarden L., Wouters D., Wolbink G.J. IgG4 production against adalimumab during long term treatment of RA patients. J. Clin. Immunol. 2012, 32:1000-1006.
10. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martínez-Martínez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., De Baets M.H., van de Winkel J.G., Aalberse R.C., Parren P.W. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
11. Hart M.H., de Vrieze H., Wouters D., Wolbink G.J., Killestein J., de Groot E.R., Aarden L.A., Rispens T. Differential effect of drug interference in immunogenicity assays. J. Immunol. Methods 2011, 372:196-203.
12. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. Draft May 2012 available from website , 2012 (accessed 8.11.12). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf.
13. Haaland P.D. Experimental Design In Biotechnology 1989, Marcel Dekker, New York.
14. Barger T.E., Kuck A.J., Chirmule N., Swanson S.J., Mytych D.T. Detection of anti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. Nephrol. Dial. Transplant. 2012, 27:688-693.
15. Stubenrauch K., Wessels U., Vogel R., Schleypen J. Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards. Anal. Biochem. 2009, 390:189-196.
16. Situ C., Wylie A.R., Douglas A., Elliott C.T. Reduction of severe bovine serum associated matrix effects on carboxymethylated dextran coated biosensor surfaces. Talanta 2008, 76:832-836.